385 related articles for article (PubMed ID: 23765220)
1. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
De Berardis D; Marini S; Fornaro M; Srinivasan V; Iasevoli F; Tomasetti C; Valchera A; Perna G; Quera-Salva MA; Martinotti G; di Giannantonio M
Int J Mol Sci; 2013 Jun; 14(6):12458-83. PubMed ID: 23765220
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine in depressive disorders: its novel mechanisms of action.
Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
[TBL] [Abstract][Full Text] [Related]
3. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
Srinivasan V; De Berardis D; Shillcutt SD; Brzezinski A
Expert Opin Investig Drugs; 2012 Oct; 21(10):1503-22. PubMed ID: 22876742
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Vimala PV; Bhutada PS; Patel FR
Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light.
Tchekalarova J; Stoynova T; Ilieva K; Mitreva R; Atanasova M
Pharmacol Biochem Behav; 2018 Aug; 171():1-9. PubMed ID: 29807067
[TBL] [Abstract][Full Text] [Related]
6. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
[TBL] [Abstract][Full Text] [Related]
7. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
[TBL] [Abstract][Full Text] [Related]
8. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
9. Melatonergic drugs in clinical practice.
Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
[TBL] [Abstract][Full Text] [Related]
10. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
[TBL] [Abstract][Full Text] [Related]
12. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
13. Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
Højgaard K; Christiansen SL; Bouzinova EV; Wiborg O
Psychopharmacology (Berl); 2018 Mar; 235(3):627-640. PubMed ID: 29151193
[TBL] [Abstract][Full Text] [Related]
14. Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.
Catena-Dell'Osso M; Marazziti D; Rotella F; Bellantuono C
Curr Med Chem; 2012; 19(3):428-37. PubMed ID: 22335516
[TBL] [Abstract][Full Text] [Related]
15. Addressing circadian rhythm disturbances in depressed patients.
Lam RW
J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Fuchs E; Simon M; Schmelting B
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S17-20. PubMed ID: 16436935
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
18. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
19. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine: An Astounding Sui-generis Antidepressant?
Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
